← Human Trials & Peer-Reviewed Studies
Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study.
Plain-language guide to PMID 12050246 (2002): double-blind randomized controlled trial of Human Growth Hormone in 25 patients.
Key Facts
- PMID
- 12050246
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Ueland T et al. (6 authors)
- DOI
- 10.1210/jcem.87.6.8549
What This Study Did, in Plain Language
What Was Tested
Researchers studied Human Growth Hormone in this randomized controlled trial publication.
Levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-3, IGFBP-5, osteocalcin, OPG, RANKL, and total protein were determined in extracts obtained after EDTA and guanidine hydrochloride extraction.
Calcium was determined after HCl hydrolysis.
Who Took Part
According to the abstract, 25 patients were involved.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The patients were allocated by chance, so the Human Growth Hormone group and the comparison group should start out alike.
Blinding on both sides kept the patients and researchers unaware of who received Human Growth Hormone.
A placebo (an inactive look-alike) gave the Human Growth Hormone group a baseline to be compared against.
What Was Measured
Levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-3, IGFBP-5, osteocalcin, OPG, RANKL, and total protein were determined in extracts obtained after EDTA and guanidine hydrochloride extraction.
Topics PubMed links to this paper include Bone and Bones, Deficiency Diseases, Glycoproteins, Human Growth Hormone, Osteocalcin, Osteoprotegerin and Receptors, Cytoplasmic and Nuclear.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Human Growth Hormone in 25 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2002 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.
Related Library Page
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.